Up­dat­ed: Eli Lil­ly blames Biden's IRA for can­cer drug dis­con­tin­u­a­tion as the new phar­ma play­book takes shape

Eli Lil­ly laid blame Tues­day af­ter­noon on Pres­i­dent Joe Biden’s In­fla­tion Re­duc­tion Act as the rea­son it scrapped a $40 mil­lion can­cer drug.

As part of its third quar­ter up­date ear­li­er Tues­day morn­ing, the Big Phar­ma re­vealed it had re­moved a Phase I drug li­censed from Fo­s­un Phar­ma, a BCL2 in­hibitor that had been un­der­go­ing stud­ies for a va­ri­ety of blood can­cers. Though the rea­son­ing had been ini­tial­ly un­clear, an Eli Lil­ly spokesper­son told End­points News in an email that “in light of the In­fla­tion Re­duc­tion Act, this pro­gram no longer met our thresh­old for con­tin­ued in­vest­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER